stockrowGrifols, S.A.
GRFSHealthcare Drug Manufacturers General
Grifols, S.A.’s revenue for fiscal 2025 (year ended December 2025) was $8.5 billion, up 9.07% from fiscal 2024.
- Revenue
- +9.37%
- EPS
- +59.8%
- Free cash flow
- +4.11%
- Total debt
- −6.08%
Quarter to September 2026, against a year earlier
Follow GRFS
Alert me
Grifols, S.A. (GRFS) Debt to equity
Grifols, S.A.'s debt to equity at the end of the quarter to 30 September 2026 was 1.1×, down 0.1× from fiscal 2025 (1.3×). Over the past ten years it has ranged from 1.0× (fiscal 2020) to 1.7× (fiscal 2021); the current reading is higher than 22% of that period. That is above the Drug Manufacturers General industry median of 0.6× and above the Healthcare sector median of 0.0×.
Debt to equity, annual
Embed this chart
Annual newest first
| Period | Debt to equity | Change |
|---|---|---|
| FY2025 | 1.3× | 7.37% |
| FY2024 | 1.2× | (14.83%) |
| FY2023 | 1.4× | 9.05% |
| FY2022 | 1.3× | (20.04%) |
| FY2022 | 1.6× | 14.01% |
| FY2021 | 1.4× | (17.35%) |
| FY2021 | 1.7× | 61.43% |
| FY2020 | 1.0× | (22.73%) |
| FY2020 | 1.4× | 28.51% |
| FY2019 | 1.1× | (28.55%) |
Quarterly newest first
| Period | Debt to equity | Change |
|---|---|---|
| Sep 2026 | 1.1× | (4.38%) |
| Jun 2026 | 1.2× | (4.85%) |
| Mar 2026 | 1.2× | (2.85%) |
| Dec 2025 | 1.3× | (1.18%) |
| 31 more quarters | Free account |
Against its own ten years
Debt to equity against peers
| Company | Debt to equity |
|---|---|
| NSRX Nasus Pharma Ltd. compare | 0.0× |
| AMRN Amarin Corporation PLC compare | 0.0× |
| SNY Sanofi compare | 0.2× |
| BIIB Biogen Inc. compare | 0.4× |
| NVO Novo Nordisk A/S compare | 0.6× |
| GRFS Grifols, S.A. | 1.1× |
| GSK GSK PLC Sponsored ADR compare | 1.3× |
| BMY Bristol Myers Squibb Company compare | 1.8× |
| OGN Organon & Co. compare | 7.2× |
| Drug Manufacturers General industry median | 0.6× |
| Healthcare sector median | 0.0× |
| Market median | 0.1× |
What Debt to equity is
Debt to Equity Ratio shows how much a company relies on borrowed money compared with the money its shareholders have in the business.
(Long Term Debt (Total) + Current Part of Debt) ÷ Shareholders Equity (Total)
More on GRFS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement